nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—CYP2D6—Gefitinib—lung cancer	0.0461	0.125	CbGbCtD
Lisuride—CYP2D6—Vinorelbine—lung cancer	0.0355	0.096	CbGbCtD
Lisuride—CYP3A4—Topotecan—lung cancer	0.032	0.0866	CbGbCtD
Lisuride—CYP3A4—Gefitinib—lung cancer	0.0293	0.0792	CbGbCtD
Lisuride—CYP3A4—Teniposide—lung cancer	0.0284	0.0768	CbGbCtD
Lisuride—CYP2D6—Erlotinib—lung cancer	0.0272	0.0737	CbGbCtD
Lisuride—CYP3A4—Vinorelbine—lung cancer	0.0226	0.061	CbGbCtD
Lisuride—CYP2D6—Vinblastine—lung cancer	0.0219	0.0592	CbGbCtD
Lisuride—CYP3A4—Crizotinib—lung cancer	0.018	0.0486	CbGbCtD
Lisuride—CYP3A4—Erlotinib—lung cancer	0.0173	0.0469	CbGbCtD
Lisuride—CYP3A4—Paclitaxel—lung cancer	0.0159	0.0429	CbGbCtD
Lisuride—CYP3A4—Irinotecan—lung cancer	0.0156	0.0423	CbGbCtD
Lisuride—CYP3A4—Vinblastine—lung cancer	0.0139	0.0376	CbGbCtD
Lisuride—CYP2D6—Doxorubicin—lung cancer	0.0134	0.0364	CbGbCtD
Lisuride—CYP3A4—Etoposide—lung cancer	0.0125	0.0339	CbGbCtD
Lisuride—CYP3A4—Docetaxel—lung cancer	0.0115	0.031	CbGbCtD
Lisuride—CYP3A4—Doxorubicin—lung cancer	0.00855	0.0231	CbGbCtD
Lisuride—HTR2A—phrenic nerve—lung cancer	0.00799	0.372	CbGeAlD
Lisuride—HTR2A—pulmonary artery—lung cancer	0.0029	0.135	CbGeAlD
Lisuride—ADRA1D—epithelium—lung cancer	0.0011	0.0511	CbGeAlD
Lisuride—Weight decreased—Paclitaxel—lung cancer	0.000869	0.00252	CcSEcCtD
Lisuride—Cough—Vinorelbine—lung cancer	0.000869	0.00251	CcSEcCtD
Lisuride—Orthostatic hypotension—Docetaxel—lung cancer	0.000861	0.00249	CcSEcCtD
Lisuride—Angiopathy—Irinotecan—lung cancer	0.000856	0.00248	CcSEcCtD
Lisuride—Cardiac disorder—Gemcitabine—lung cancer	0.000853	0.00247	CcSEcCtD
Lisuride—Immune system disorder—Irinotecan—lung cancer	0.000852	0.00247	CcSEcCtD
Lisuride—Mediastinal disorder—Irinotecan—lung cancer	0.00085	0.00246	CcSEcCtD
Lisuride—Insomnia—Erlotinib—lung cancer	0.00085	0.00246	CcSEcCtD
Lisuride—Decreased appetite—Vinblastine—lung cancer	0.00085	0.00246	CcSEcCtD
Lisuride—Dyspnoea—Topotecan—lung cancer	0.000847	0.00245	CcSEcCtD
Lisuride—Dyspnoea—Erlotinib—lung cancer	0.000838	0.00242	CcSEcCtD
Lisuride—Constipation—Vinblastine—lung cancer	0.000836	0.00242	CcSEcCtD
Lisuride—Angiopathy—Gemcitabine—lung cancer	0.000833	0.00241	CcSEcCtD
Lisuride—Immune system disorder—Gemcitabine—lung cancer	0.00083	0.0024	CcSEcCtD
Lisuride—Mediastinal disorder—Gemcitabine—lung cancer	0.000828	0.0024	CcSEcCtD
Lisuride—Decreased appetite—Topotecan—lung cancer	0.000826	0.00239	CcSEcCtD
Lisuride—Gastrointestinal disorder—Topotecan—lung cancer	0.00082	0.00237	CcSEcCtD
Lisuride—Fatigue—Topotecan—lung cancer	0.000819	0.00237	CcSEcCtD
Lisuride—Decreased appetite—Erlotinib—lung cancer	0.000817	0.00236	CcSEcCtD
Lisuride—Vomiting—Teniposide—lung cancer	0.000815	0.00236	CcSEcCtD
Lisuride—Constipation—Topotecan—lung cancer	0.000812	0.00235	CcSEcCtD
Lisuride—Gastrointestinal disorder—Erlotinib—lung cancer	0.000811	0.00235	CcSEcCtD
Lisuride—Fatigue—Erlotinib—lung cancer	0.00081	0.00234	CcSEcCtD
Lisuride—Infection—Vinorelbine—lung cancer	0.000807	0.00234	CcSEcCtD
Lisuride—Feeling abnormal—Vinblastine—lung cancer	0.000806	0.00233	CcSEcCtD
Lisuride—Constipation—Erlotinib—lung cancer	0.000803	0.00233	CcSEcCtD
Lisuride—Headache—Teniposide—lung cancer	0.000803	0.00232	CcSEcCtD
Lisuride—Nervous system disorder—Vinorelbine—lung cancer	0.000797	0.00231	CcSEcCtD
Lisuride—Cardiac disorder—Cisplatin—lung cancer	0.000795	0.0023	CcSEcCtD
Lisuride—Tachycardia—Vinorelbine—lung cancer	0.000793	0.00229	CcSEcCtD
Lisuride—ADRB1—bronchus—lung cancer	0.000786	0.0366	CbGeAlD
Lisuride—Feeling abnormal—Topotecan—lung cancer	0.000783	0.00227	CcSEcCtD
Lisuride—Anorexia—Vinorelbine—lung cancer	0.000774	0.00224	CcSEcCtD
Lisuride—Immune system disorder—Cisplatin—lung cancer	0.000773	0.00224	CcSEcCtD
Lisuride—Mediastinal disorder—Cisplatin—lung cancer	0.000772	0.00223	CcSEcCtD
Lisuride—Oedema peripheral—Paclitaxel—lung cancer	0.000758	0.00219	CcSEcCtD
Lisuride—Malnutrition—Cisplatin—lung cancer	0.000745	0.00216	CcSEcCtD
Lisuride—Weight increased—Docetaxel—lung cancer	0.000741	0.00215	CcSEcCtD
Lisuride—DRD2—respiratory system—lung cancer	0.00074	0.0344	CbGeAlD
Lisuride—Vertigo—Irinotecan—lung cancer	0.000738	0.00213	CcSEcCtD
Lisuride—Weight decreased—Docetaxel—lung cancer	0.000737	0.00213	CcSEcCtD
Lisuride—Syncope—Irinotecan—lung cancer	0.000736	0.00213	CcSEcCtD
Lisuride—Cardiac disorder—Etoposide—lung cancer	0.000728	0.00211	CcSEcCtD
Lisuride—Dyspnoea—Vinorelbine—lung cancer	0.000724	0.0021	CcSEcCtD
Lisuride—Cough—Irinotecan—lung cancer	0.000716	0.00207	CcSEcCtD
Lisuride—Cardiac disorder—Paclitaxel—lung cancer	0.000714	0.00207	CcSEcCtD
Lisuride—Angiopathy—Etoposide—lung cancer	0.000712	0.00206	CcSEcCtD
Lisuride—Immune system disorder—Etoposide—lung cancer	0.000709	0.00205	CcSEcCtD
Lisuride—Mediastinal disorder—Etoposide—lung cancer	0.000707	0.00205	CcSEcCtD
Lisuride—Decreased appetite—Vinorelbine—lung cancer	0.000706	0.00204	CcSEcCtD
Lisuride—Asthenia—Vinblastine—lung cancer	0.000701	0.00203	CcSEcCtD
Lisuride—Gastrointestinal disorder—Vinorelbine—lung cancer	0.000701	0.00203	CcSEcCtD
Lisuride—Fatigue—Vinorelbine—lung cancer	0.0007	0.00203	CcSEcCtD
Lisuride—Cough—Gemcitabine—lung cancer	0.000698	0.00202	CcSEcCtD
Lisuride—Angiopathy—Paclitaxel—lung cancer	0.000698	0.00202	CcSEcCtD
Lisuride—Constipation—Vinorelbine—lung cancer	0.000695	0.00201	CcSEcCtD
Lisuride—Immune system disorder—Paclitaxel—lung cancer	0.000695	0.00201	CcSEcCtD
Lisuride—Mediastinal disorder—Paclitaxel—lung cancer	0.000693	0.00201	CcSEcCtD
Lisuride—Asthenia—Topotecan—lung cancer	0.000681	0.00197	CcSEcCtD
Lisuride—Confusional state—Irinotecan—lung cancer	0.000676	0.00196	CcSEcCtD
Lisuride—Asthenia—Erlotinib—lung cancer	0.000674	0.00195	CcSEcCtD
Lisuride—Mental disorder—Paclitaxel—lung cancer	0.000674	0.00195	CcSEcCtD
Lisuride—Malnutrition—Paclitaxel—lung cancer	0.00067	0.00194	CcSEcCtD
Lisuride—Feeling abnormal—Vinorelbine—lung cancer	0.000669	0.00194	CcSEcCtD
Lisuride—Infection—Irinotecan—lung cancer	0.000666	0.00193	CcSEcCtD
Lisuride—ADRB1—cardiac atrium—lung cancer	0.000663	0.0309	CbGeAlD
Lisuride—Nervous system disorder—Irinotecan—lung cancer	0.000657	0.0019	CcSEcCtD
Lisuride—Infection—Gemcitabine—lung cancer	0.000648	0.00188	CcSEcCtD
Lisuride—Hyperhidrosis—Irinotecan—lung cancer	0.000648	0.00187	CcSEcCtD
Lisuride—Dizziness—Vinblastine—lung cancer	0.000646	0.00187	CcSEcCtD
Lisuride—Oedema peripheral—Docetaxel—lung cancer	0.000642	0.00186	CcSEcCtD
Lisuride—Nervous system disorder—Gemcitabine—lung cancer	0.00064	0.00185	CcSEcCtD
Lisuride—Anorexia—Irinotecan—lung cancer	0.000639	0.00185	CcSEcCtD
Lisuride—Anxiety—Cisplatin—lung cancer	0.000632	0.00183	CcSEcCtD
Lisuride—Hyperhidrosis—Gemcitabine—lung cancer	0.000631	0.00183	CcSEcCtD
Lisuride—Dizziness—Topotecan—lung cancer	0.000628	0.00182	CcSEcCtD
Lisuride—Anorexia—Gemcitabine—lung cancer	0.000622	0.0018	CcSEcCtD
Lisuride—Vomiting—Vinblastine—lung cancer	0.000622	0.0018	CcSEcCtD
Lisuride—Dizziness—Erlotinib—lung cancer	0.000621	0.0018	CcSEcCtD
Lisuride—Vertigo—Etoposide—lung cancer	0.000614	0.00178	CcSEcCtD
Lisuride—Headache—Vinblastine—lung cancer	0.000612	0.00177	CcSEcCtD
Lisuride—Insomnia—Irinotecan—lung cancer	0.000606	0.00175	CcSEcCtD
Lisuride—Cardiac disorder—Docetaxel—lung cancer	0.000605	0.00175	CcSEcCtD
Lisuride—Infection—Cisplatin—lung cancer	0.000604	0.00175	CcSEcCtD
Lisuride—Vomiting—Topotecan—lung cancer	0.000604	0.00175	CcSEcCtD
Lisuride—Vertigo—Paclitaxel—lung cancer	0.000602	0.00174	CcSEcCtD
Lisuride—Syncope—Paclitaxel—lung cancer	0.0006	0.00174	CcSEcCtD
Lisuride—Vomiting—Erlotinib—lung cancer	0.000597	0.00173	CcSEcCtD
Lisuride—Dyspnoea—Irinotecan—lung cancer	0.000597	0.00173	CcSEcCtD
Lisuride—Nervous system disorder—Cisplatin—lung cancer	0.000597	0.00173	CcSEcCtD
Lisuride—Cough—Etoposide—lung cancer	0.000596	0.00172	CcSEcCtD
Lisuride—Somnolence—Irinotecan—lung cancer	0.000596	0.00172	CcSEcCtD
Lisuride—Headache—Topotecan—lung cancer	0.000595	0.00172	CcSEcCtD
Lisuride—Tachycardia—Cisplatin—lung cancer	0.000594	0.00172	CcSEcCtD
Lisuride—ADRA2C—bronchus—lung cancer	0.000592	0.0276	CbGeAlD
Lisuride—Palpitations—Paclitaxel—lung cancer	0.000592	0.00171	CcSEcCtD
Lisuride—Angiopathy—Docetaxel—lung cancer	0.000591	0.00171	CcSEcCtD
Lisuride—Insomnia—Gemcitabine—lung cancer	0.00059	0.00171	CcSEcCtD
Lisuride—Immune system disorder—Docetaxel—lung cancer	0.000589	0.0017	CcSEcCtD
Lisuride—Headache—Erlotinib—lung cancer	0.000589	0.0017	CcSEcCtD
Lisuride—Hyperhidrosis—Cisplatin—lung cancer	0.000588	0.0017	CcSEcCtD
Lisuride—Mediastinal disorder—Docetaxel—lung cancer	0.000588	0.0017	CcSEcCtD
Lisuride—Cough—Paclitaxel—lung cancer	0.000584	0.00169	CcSEcCtD
Lisuride—Asthenia—Vinorelbine—lung cancer	0.000583	0.00169	CcSEcCtD
Lisuride—Decreased appetite—Irinotecan—lung cancer	0.000582	0.00169	CcSEcCtD
Lisuride—Dyspnoea—Gemcitabine—lung cancer	0.000582	0.00168	CcSEcCtD
Lisuride—Somnolence—Gemcitabine—lung cancer	0.00058	0.00168	CcSEcCtD
Lisuride—Anorexia—Cisplatin—lung cancer	0.00058	0.00168	CcSEcCtD
Lisuride—Gastrointestinal disorder—Irinotecan—lung cancer	0.000578	0.00167	CcSEcCtD
Lisuride—Fatigue—Irinotecan—lung cancer	0.000578	0.00167	CcSEcCtD
Lisuride—Constipation—Irinotecan—lung cancer	0.000573	0.00166	CcSEcCtD
Lisuride—Mental disorder—Docetaxel—lung cancer	0.000571	0.00165	CcSEcCtD
Lisuride—Anxiety—Paclitaxel—lung cancer	0.000568	0.00164	CcSEcCtD
Lisuride—Malnutrition—Docetaxel—lung cancer	0.000568	0.00164	CcSEcCtD
Lisuride—Decreased appetite—Gemcitabine—lung cancer	0.000567	0.00164	CcSEcCtD
Lisuride—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000563	0.00163	CcSEcCtD
Lisuride—Abdominal discomfort—Methotrexate—lung cancer	0.000563	0.00163	CcSEcCtD
Lisuride—Fatigue—Gemcitabine—lung cancer	0.000563	0.00163	CcSEcCtD
Lisuride—Confusional state—Etoposide—lung cancer	0.000562	0.00163	CcSEcCtD
Lisuride—Constipation—Gemcitabine—lung cancer	0.000558	0.00162	CcSEcCtD
Lisuride—Dry mouth—Paclitaxel—lung cancer	0.000557	0.00161	CcSEcCtD
Lisuride—Infection—Etoposide—lung cancer	0.000554	0.0016	CcSEcCtD
Lisuride—Feeling abnormal—Irinotecan—lung cancer	0.000552	0.0016	CcSEcCtD
Lisuride—Confusional state—Paclitaxel—lung cancer	0.000551	0.00159	CcSEcCtD
Lisuride—Dehydration—Doxorubicin—lung cancer	0.000547	0.00158	CcSEcCtD
Lisuride—Tachycardia—Etoposide—lung cancer	0.000544	0.00157	CcSEcCtD
Lisuride—Infection—Paclitaxel—lung cancer	0.000543	0.00157	CcSEcCtD
Lisuride—Dyspnoea—Cisplatin—lung cancer	0.000542	0.00157	CcSEcCtD
Lisuride—Hyperhidrosis—Etoposide—lung cancer	0.000539	0.00156	CcSEcCtD
Lisuride—Feeling abnormal—Gemcitabine—lung cancer	0.000538	0.00156	CcSEcCtD
Lisuride—Dizziness—Vinorelbine—lung cancer	0.000537	0.00155	CcSEcCtD
Lisuride—Orthostatic hypotension—Doxorubicin—lung cancer	0.000537	0.00155	CcSEcCtD
Lisuride—Nervous system disorder—Paclitaxel—lung cancer	0.000536	0.00155	CcSEcCtD
Lisuride—Tachycardia—Paclitaxel—lung cancer	0.000533	0.00154	CcSEcCtD
Lisuride—ADRA2C—trachea—lung cancer	0.000532	0.0247	CbGeAlD
Lisuride—Anorexia—Etoposide—lung cancer	0.000531	0.00154	CcSEcCtD
Lisuride—Decreased appetite—Cisplatin—lung cancer	0.000529	0.00153	CcSEcCtD
Lisuride—Hyperhidrosis—Paclitaxel—lung cancer	0.000528	0.00153	CcSEcCtD
Lisuride—Gastrointestinal disorder—Cisplatin—lung cancer	0.000525	0.00152	CcSEcCtD
Lisuride—Anorexia—Paclitaxel—lung cancer	0.000521	0.00151	CcSEcCtD
Lisuride—Vomiting—Vinorelbine—lung cancer	0.000517	0.0015	CcSEcCtD
Lisuride—Headache—Vinorelbine—lung cancer	0.000509	0.00147	CcSEcCtD
Lisuride—Syncope—Docetaxel—lung cancer	0.000509	0.00147	CcSEcCtD
Lisuride—ADRB1—lung—lung cancer	0.000507	0.0236	CbGeAlD
Lisuride—Sweating—Methotrexate—lung cancer	0.000502	0.00145	CcSEcCtD
Lisuride—Palpitations—Docetaxel—lung cancer	0.000502	0.00145	CcSEcCtD
Lisuride—Feeling abnormal—Cisplatin—lung cancer	0.000501	0.00145	CcSEcCtD
Lisuride—ADRA2C—cardiac atrium—lung cancer	0.000499	0.0232	CbGeAlD
Lisuride—Dyspnoea—Etoposide—lung cancer	0.000497	0.00144	CcSEcCtD
Lisuride—Somnolence—Etoposide—lung cancer	0.000495	0.00143	CcSEcCtD
Lisuride—Cough—Docetaxel—lung cancer	0.000495	0.00143	CcSEcCtD
Lisuride—Insomnia—Paclitaxel—lung cancer	0.000494	0.00143	CcSEcCtD
Lisuride—HTR2A—respiratory system—lung cancer	0.000488	0.0227	CbGeAlD
Lisuride—Dyspnoea—Paclitaxel—lung cancer	0.000487	0.00141	CcSEcCtD
Lisuride—Somnolence—Paclitaxel—lung cancer	0.000486	0.00141	CcSEcCtD
Lisuride—HTR2B—lung—lung cancer	0.000485	0.0226	CbGeAlD
Lisuride—Decreased appetite—Etoposide—lung cancer	0.000484	0.0014	CcSEcCtD
Lisuride—Gastrointestinal disorder—Etoposide—lung cancer	0.000481	0.00139	CcSEcCtD
Lisuride—Asthenia—Irinotecan—lung cancer	0.000481	0.00139	CcSEcCtD
Lisuride—Fatigue—Etoposide—lung cancer	0.00048	0.00139	CcSEcCtD
Lisuride—Constipation—Etoposide—lung cancer	0.000477	0.00138	CcSEcCtD
Lisuride—Decreased appetite—Paclitaxel—lung cancer	0.000475	0.00137	CcSEcCtD
Lisuride—Dry mouth—Docetaxel—lung cancer	0.000473	0.00137	CcSEcCtD
Lisuride—ADRA2A—bronchus—lung cancer	0.000472	0.022	CbGeAlD
Lisuride—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000472	0.00137	CcSEcCtD
Lisuride—Fatigue—Paclitaxel—lung cancer	0.000471	0.00136	CcSEcCtD
Lisuride—Asthenia—Gemcitabine—lung cancer	0.000468	0.00136	CcSEcCtD
Lisuride—Constipation—Paclitaxel—lung cancer	0.000467	0.00135	CcSEcCtD
Lisuride—Confusional state—Docetaxel—lung cancer	0.000467	0.00135	CcSEcCtD
Lisuride—Weight increased—Doxorubicin—lung cancer	0.000463	0.00134	CcSEcCtD
Lisuride—Infection—Docetaxel—lung cancer	0.00046	0.00133	CcSEcCtD
Lisuride—Weight decreased—Doxorubicin—lung cancer	0.00046	0.00133	CcSEcCtD
Lisuride—Feeling abnormal—Etoposide—lung cancer	0.000459	0.00133	CcSEcCtD
Lisuride—Nervous system disorder—Docetaxel—lung cancer	0.000454	0.00131	CcSEcCtD
Lisuride—Tachycardia—Docetaxel—lung cancer	0.000452	0.00131	CcSEcCtD
Lisuride—Feeling abnormal—Paclitaxel—lung cancer	0.00045	0.0013	CcSEcCtD
Lisuride—Dizziness—Irinotecan—lung cancer	0.000443	0.00128	CcSEcCtD
Lisuride—Anorexia—Docetaxel—lung cancer	0.000441	0.00128	CcSEcCtD
Lisuride—Asthenia—Cisplatin—lung cancer	0.000436	0.00126	CcSEcCtD
Lisuride—Cardiac disorder—Methotrexate—lung cancer	0.000436	0.00126	CcSEcCtD
Lisuride—Sweating—Doxorubicin—lung cancer	0.000434	0.00126	CcSEcCtD
Lisuride—Angiopathy—Methotrexate—lung cancer	0.000426	0.00123	CcSEcCtD
Lisuride—Vomiting—Irinotecan—lung cancer	0.000426	0.00123	CcSEcCtD
Lisuride—Immune system disorder—Methotrexate—lung cancer	0.000424	0.00123	CcSEcCtD
Lisuride—ADRA2A—trachea—lung cancer	0.000424	0.0197	CbGeAlD
Lisuride—Mediastinal disorder—Methotrexate—lung cancer	0.000423	0.00123	CcSEcCtD
Lisuride—Headache—Irinotecan—lung cancer	0.00042	0.00121	CcSEcCtD
Lisuride—Insomnia—Docetaxel—lung cancer	0.000419	0.00121	CcSEcCtD
Lisuride—Vomiting—Gemcitabine—lung cancer	0.000415	0.0012	CcSEcCtD
Lisuride—Dyspnoea—Docetaxel—lung cancer	0.000413	0.0012	CcSEcCtD
Lisuride—Somnolence—Docetaxel—lung cancer	0.000412	0.00119	CcSEcCtD
Lisuride—Mental disorder—Methotrexate—lung cancer	0.000412	0.00119	CcSEcCtD
Lisuride—Malnutrition—Methotrexate—lung cancer	0.000409	0.00118	CcSEcCtD
Lisuride—Headache—Gemcitabine—lung cancer	0.000409	0.00118	CcSEcCtD
Lisuride—HTR2A—epithelium—lung cancer	0.000408	0.019	CbGeAlD
Lisuride—Decreased appetite—Docetaxel—lung cancer	0.000403	0.00117	CcSEcCtD
Lisuride—Oedema peripheral—Doxorubicin—lung cancer	0.000401	0.00116	CcSEcCtD
Lisuride—Gastrointestinal disorder—Docetaxel—lung cancer	0.0004	0.00116	CcSEcCtD
Lisuride—Asthenia—Etoposide—lung cancer	0.0004	0.00116	CcSEcCtD
Lisuride—Fatigue—Docetaxel—lung cancer	0.000399	0.00116	CcSEcCtD
Lisuride—ADRA2A—cardiac atrium—lung cancer	0.000399	0.0185	CbGeAlD
Lisuride—Constipation—Docetaxel—lung cancer	0.000396	0.00115	CcSEcCtD
Lisuride—DRD2—lung—lung cancer	0.000393	0.0183	CbGeAlD
Lisuride—Asthenia—Paclitaxel—lung cancer	0.000392	0.00113	CcSEcCtD
Lisuride—Vomiting—Cisplatin—lung cancer	0.000387	0.00112	CcSEcCtD
Lisuride—ADRA2C—lung—lung cancer	0.000382	0.0178	CbGeAlD
Lisuride—Feeling abnormal—Docetaxel—lung cancer	0.000382	0.0011	CcSEcCtD
Lisuride—Cardiac disorder—Doxorubicin—lung cancer	0.000378	0.00109	CcSEcCtD
Lisuride—Angiopathy—Doxorubicin—lung cancer	0.000369	0.00107	CcSEcCtD
Lisuride—Dizziness—Etoposide—lung cancer	0.000369	0.00107	CcSEcCtD
Lisuride—Immune system disorder—Doxorubicin—lung cancer	0.000367	0.00106	CcSEcCtD
Lisuride—Vertigo—Methotrexate—lung cancer	0.000367	0.00106	CcSEcCtD
Lisuride—Mediastinal disorder—Doxorubicin—lung cancer	0.000367	0.00106	CcSEcCtD
Lisuride—Dizziness—Paclitaxel—lung cancer	0.000361	0.00105	CcSEcCtD
Lisuride—HTR2A—trachea—lung cancer	0.000361	0.0168	CbGeAlD
Lisuride—Cough—Methotrexate—lung cancer	0.000357	0.00103	CcSEcCtD
Lisuride—Mental disorder—Doxorubicin—lung cancer	0.000356	0.00103	CcSEcCtD
Lisuride—Vomiting—Etoposide—lung cancer	0.000354	0.00103	CcSEcCtD
Lisuride—Malnutrition—Doxorubicin—lung cancer	0.000354	0.00103	CcSEcCtD
Lisuride—Headache—Etoposide—lung cancer	0.000349	0.00101	CcSEcCtD
Lisuride—Vomiting—Paclitaxel—lung cancer	0.000347	0.00101	CcSEcCtD
Lisuride—Headache—Paclitaxel—lung cancer	0.000342	0.000991	CcSEcCtD
Lisuride—Confusional state—Methotrexate—lung cancer	0.000337	0.000974	CcSEcCtD
Lisuride—Asthenia—Docetaxel—lung cancer	0.000332	0.000962	CcSEcCtD
Lisuride—HTR2B—lymph node—lung cancer	0.000332	0.0154	CbGeAlD
Lisuride—Infection—Methotrexate—lung cancer	0.000332	0.00096	CcSEcCtD
Lisuride—Nervous system disorder—Methotrexate—lung cancer	0.000327	0.000948	CcSEcCtD
Lisuride—Hyperhidrosis—Methotrexate—lung cancer	0.000323	0.000934	CcSEcCtD
Lisuride—Vertigo—Doxorubicin—lung cancer	0.000318	0.000921	CcSEcCtD
Lisuride—Anorexia—Methotrexate—lung cancer	0.000318	0.000921	CcSEcCtD
Lisuride—Syncope—Doxorubicin—lung cancer	0.000318	0.000919	CcSEcCtD
Lisuride—Palpitations—Doxorubicin—lung cancer	0.000313	0.000906	CcSEcCtD
Lisuride—Cough—Doxorubicin—lung cancer	0.000309	0.000895	CcSEcCtD
Lisuride—Dizziness—Docetaxel—lung cancer	0.000306	0.000887	CcSEcCtD
Lisuride—ADRA2A—lung—lung cancer	0.000305	0.0142	CbGeAlD
Lisuride—Insomnia—Methotrexate—lung cancer	0.000302	0.000874	CcSEcCtD
Lisuride—Anxiety—Doxorubicin—lung cancer	0.0003	0.00087	CcSEcCtD
Lisuride—Dyspnoea—Methotrexate—lung cancer	0.000298	0.000861	CcSEcCtD
Lisuride—Somnolence—Methotrexate—lung cancer	0.000297	0.000859	CcSEcCtD
Lisuride—Dry mouth—Doxorubicin—lung cancer	0.000295	0.000854	CcSEcCtD
Lisuride—Vomiting—Docetaxel—lung cancer	0.000294	0.000852	CcSEcCtD
Lisuride—Confusional state—Doxorubicin—lung cancer	0.000291	0.000844	CcSEcCtD
Lisuride—Decreased appetite—Methotrexate—lung cancer	0.00029	0.00084	CcSEcCtD
Lisuride—Headache—Docetaxel—lung cancer	0.00029	0.00084	CcSEcCtD
Lisuride—Gastrointestinal disorder—Methotrexate—lung cancer	0.000288	0.000834	CcSEcCtD
Lisuride—Fatigue—Methotrexate—lung cancer	0.000288	0.000833	CcSEcCtD
Lisuride—Infection—Doxorubicin—lung cancer	0.000287	0.000831	CcSEcCtD
Lisuride—Nervous system disorder—Doxorubicin—lung cancer	0.000283	0.000821	CcSEcCtD
Lisuride—Tachycardia—Doxorubicin—lung cancer	0.000282	0.000817	CcSEcCtD
Lisuride—Hyperhidrosis—Doxorubicin—lung cancer	0.000279	0.000809	CcSEcCtD
Lisuride—Anorexia—Doxorubicin—lung cancer	0.000276	0.000798	CcSEcCtD
Lisuride—Feeling abnormal—Methotrexate—lung cancer	0.000275	0.000796	CcSEcCtD
Lisuride—Insomnia—Doxorubicin—lung cancer	0.000261	0.000757	CcSEcCtD
Lisuride—ADRA2C—lymph node—lung cancer	0.000261	0.0122	CbGeAlD
Lisuride—HTR2A—lung—lung cancer	0.000259	0.0121	CbGeAlD
Lisuride—Dyspnoea—Doxorubicin—lung cancer	0.000258	0.000746	CcSEcCtD
Lisuride—Somnolence—Doxorubicin—lung cancer	0.000257	0.000744	CcSEcCtD
Lisuride—Decreased appetite—Doxorubicin—lung cancer	0.000251	0.000727	CcSEcCtD
Lisuride—Gastrointestinal disorder—Doxorubicin—lung cancer	0.00025	0.000722	CcSEcCtD
Lisuride—Fatigue—Doxorubicin—lung cancer	0.000249	0.000721	CcSEcCtD
Lisuride—Constipation—Doxorubicin—lung cancer	0.000247	0.000715	CcSEcCtD
Lisuride—Asthenia—Methotrexate—lung cancer	0.00024	0.000693	CcSEcCtD
Lisuride—Feeling abnormal—Doxorubicin—lung cancer	0.000238	0.000689	CcSEcCtD
Lisuride—Dizziness—Methotrexate—lung cancer	0.000221	0.000639	CcSEcCtD
Lisuride—Vomiting—Methotrexate—lung cancer	0.000212	0.000614	CcSEcCtD
Lisuride—Headache—Methotrexate—lung cancer	0.000209	0.000605	CcSEcCtD
Lisuride—ADRA2A—lymph node—lung cancer	0.000208	0.0097	CbGeAlD
Lisuride—Asthenia—Doxorubicin—lung cancer	0.000207	0.0006	CcSEcCtD
Lisuride—Dizziness—Doxorubicin—lung cancer	0.000191	0.000553	CcSEcCtD
Lisuride—Vomiting—Doxorubicin—lung cancer	0.000184	0.000532	CcSEcCtD
Lisuride—Headache—Doxorubicin—lung cancer	0.000181	0.000524	CcSEcCtD
Lisuride—DRD1—Signaling Pathways—MYC—lung cancer	9.64e-06	3.66e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CXCL8—lung cancer	9.58e-06	3.64e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—SRC—lung cancer	9.58e-06	3.64e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MMP9—lung cancer	9.56e-06	3.63e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—STK11—lung cancer	9.56e-06	3.63e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—HRAS—lung cancer	9.52e-06	3.62e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CDKN1A—lung cancer	9.52e-06	3.62e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EP300—lung cancer	9.51e-06	3.61e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MYC—lung cancer	9.51e-06	3.61e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MYC—lung cancer	9.51e-06	3.61e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTEN—lung cancer	9.5e-06	3.61e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EP300—lung cancer	9.46e-06	3.59e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—KRAS—lung cancer	9.45e-06	3.59e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PIK3CA—lung cancer	9.44e-06	3.58e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—EGFR—lung cancer	9.43e-06	3.58e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—VEGFA—lung cancer	9.42e-06	3.58e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—lung cancer	9.42e-06	3.58e-05	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—lung cancer	9.41e-06	3.57e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTEN—lung cancer	9.38e-06	3.56e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	9.36e-06	3.56e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—VEGFA—lung cancer	9.33e-06	3.54e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—lung cancer	9.33e-06	3.54e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MDM2—lung cancer	9.33e-06	3.54e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CASP3—lung cancer	9.32e-06	3.54e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL2—lung cancer	9.31e-06	3.53e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—NRAS—lung cancer	9.3e-06	3.53e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—EGFR—lung cancer	9.3e-06	3.53e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—EGFR—lung cancer	9.3e-06	3.53e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—RAF1—lung cancer	9.29e-06	3.53e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—lung cancer	9.27e-06	3.52e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—IL6—lung cancer	9.26e-06	3.52e-05	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—lung cancer	9.26e-06	3.52e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—SRC—lung cancer	9.25e-06	3.51e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—lung cancer	9.24e-06	3.51e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PIK3CA—lung cancer	9.24e-06	3.51e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CG—lung cancer	9.23e-06	3.5e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—NRAS—lung cancer	9.22e-06	3.5e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EP300—lung cancer	9.21e-06	3.5e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—SRC—lung cancer	9.2e-06	3.49e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—ERBB2—lung cancer	9.19e-06	3.49e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CASP3—lung cancer	9.17e-06	3.48e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL2—lung cancer	9.16e-06	3.48e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—lung cancer	9.13e-06	3.47e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—IL6—lung cancer	9.11e-06	3.46e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PIK3CA—lung cancer	9.09e-06	3.45e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCND1—lung cancer	9.07e-06	3.45e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MTOR—lung cancer	9.07e-06	3.45e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	9.07e-06	3.45e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EP300—lung cancer	9.06e-06	3.44e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—JUN—lung cancer	9.06e-06	3.44e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—VEGFA—lung cancer	9.01e-06	3.42e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—VEGFA—lung cancer	8.96e-06	3.4e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—SRC—lung cancer	8.95e-06	3.4e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—EP300—lung cancer	8.94e-06	3.4e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—lung cancer	8.94e-06	3.39e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCND1—lung cancer	8.93e-06	3.39e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—lung cancer	8.92e-06	3.39e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK3—lung cancer	8.91e-06	3.38e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—JUN—lung cancer	8.91e-06	3.38e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—KRAS—lung cancer	8.91e-06	3.38e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—NRAS—lung cancer	8.9e-06	3.38e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—lung cancer	8.88e-06	3.37e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—NRAS—lung cancer	8.85e-06	3.36e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTP1—lung cancer	8.84e-06	3.36e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK3—lung cancer	8.83e-06	3.35e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—SRC—lung cancer	8.81e-06	3.35e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MMP9—lung cancer	8.81e-06	3.35e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—lung cancer	8.79e-06	3.34e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—KRAS—lung cancer	8.79e-06	3.34e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—KRAS—lung cancer	8.79e-06	3.34e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—POMC—lung cancer	8.78e-06	3.34e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CDKN1A—lung cancer	8.78e-06	3.33e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTEN—lung cancer	8.76e-06	3.33e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—HRAS—lung cancer	8.73e-06	3.31e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CXCL8—lung cancer	8.72e-06	3.31e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—VEGFA—lung cancer	8.72e-06	3.31e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PIK3CA—lung cancer	8.68e-06	3.3e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MMP9—lung cancer	8.67e-06	3.29e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—lung cancer	8.67e-06	3.29e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—HRAS—lung cancer	8.66e-06	3.29e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CDKN1A—lung cancer	8.64e-06	3.28e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—lung cancer	8.63e-06	3.28e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTEN—lung cancer	8.62e-06	3.27e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—NRAS—lung cancer	8.61e-06	3.27e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CAT—lung cancer	8.6e-06	3.27e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—lung cancer	8.59e-06	3.26e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—VEGFA—lung cancer	8.58e-06	3.26e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—CREBBP—lung cancer	8.56e-06	3.25e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—HRAS—lung cancer	8.55e-06	3.25e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—lung cancer	8.54e-06	3.24e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK3—lung cancer	8.52e-06	3.24e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—lung cancer	8.5e-06	3.23e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK3—lung cancer	8.48e-06	3.22e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—EGFR—lung cancer	8.48e-06	3.22e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—NRAS—lung cancer	8.48e-06	3.22e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	8.42e-06	3.2e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—HRAS—lung cancer	8.41e-06	3.19e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—lung cancer	8.41e-06	3.19e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—EGFR—lung cancer	8.4e-06	3.19e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—lung cancer	8.4e-06	3.19e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ABCB1—lung cancer	8.37e-06	3.18e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—IL6—lung cancer	8.35e-06	3.17e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EP300—lung cancer	8.35e-06	3.17e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CASP3—lung cancer	8.35e-06	3.17e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL2—lung cancer	8.33e-06	3.16e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—IL6—lung cancer	8.29e-06	3.15e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—lung cancer	8.29e-06	3.15e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK3—lung cancer	8.25e-06	3.13e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—lung cancer	8.25e-06	3.13e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—TYMS—lung cancer	8.22e-06	3.12e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EP300—lung cancer	8.22e-06	3.12e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PIK3CA—lung cancer	8.18e-06	3.11e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—IL6—lung cancer	8.18e-06	3.11e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PIK3CA—lung cancer	8.14e-06	3.09e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTM1—lung cancer	8.13e-06	3.09e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCND1—lung cancer	8.12e-06	3.08e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—SRC—lung cancer	8.12e-06	3.08e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK3—lung cancer	8.12e-06	3.08e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CD—lung cancer	8.11e-06	3.08e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EGFR—lung cancer	8.11e-06	3.08e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—JUN—lung cancer	8.11e-06	3.08e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	8.08e-06	3.07e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PIK3CA—lung cancer	8.08e-06	3.07e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EGFR—lung cancer	8.07e-06	3.06e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—IL6—lung cancer	8.05e-06	3.06e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—HRAS—lung cancer	8.03e-06	3.05e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—lung cancer	8.02e-06	3.05e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—KRAS—lung cancer	8.01e-06	3.04e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—ALB—lung cancer	8.01e-06	3.04e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—SRC—lung cancer	7.99e-06	3.03e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—KRAS—lung cancer	7.94e-06	3.01e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—lung cancer	7.92e-06	3.01e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—VEGFA—lung cancer	7.91e-06	3e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—lung cancer	7.9e-06	3e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MMP9—lung cancer	7.89e-06	2.99e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	7.86e-06	2.98e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EGFR—lung cancer	7.85e-06	2.98e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTEN—lung cancer	7.84e-06	2.98e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—lung cancer	7.83e-06	2.97e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NRAS—lung cancer	7.81e-06	2.97e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—lung cancer	7.81e-06	2.97e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—lung cancer	7.81e-06	2.97e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—VEGFA—lung cancer	7.78e-06	2.96e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EGFR—lung cancer	7.72e-06	2.93e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—lung cancer	7.71e-06	2.93e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—lung cancer	7.71e-06	2.93e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CYP1A1—lung cancer	7.7e-06	2.92e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NRAS—lung cancer	7.69e-06	2.92e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—IL6—lung cancer	7.68e-06	2.92e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—KRAS—lung cancer	7.66e-06	2.91e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—lung cancer	7.65e-06	2.9e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ERCC2—lung cancer	7.64e-06	2.9e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—KRAS—lung cancer	7.62e-06	2.89e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—HRAS—lung cancer	7.57e-06	2.88e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—lung cancer	7.55e-06	2.87e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK3—lung cancer	7.48e-06	2.84e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EP300—lung cancer	7.48e-06	2.84e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—HRAS—lung cancer	7.47e-06	2.84e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—HRAS—lung cancer	7.47e-06	2.84e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—lung cancer	7.43e-06	2.82e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—KRAS—lung cancer	7.41e-06	2.81e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK3—lung cancer	7.36e-06	2.8e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PIK3CA—lung cancer	7.36e-06	2.79e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—KRAS—lung cancer	7.3e-06	2.77e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	7.29e-06	2.77e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—lung cancer	7.28e-06	2.76e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—SRC—lung cancer	7.27e-06	2.76e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—IL6—lung cancer	7.25e-06	2.75e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—lung cancer	7.16e-06	2.72e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—IL6—lung cancer	7.15e-06	2.72e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—IL6—lung cancer	7.15e-06	2.72e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EGFR—lung cancer	7.12e-06	2.7e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—lung cancer	7.12e-06	2.7e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—lung cancer	7.09e-06	2.69e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—VEGFA—lung cancer	7.08e-06	2.69e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CB—lung cancer	7.07e-06	2.69e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—lung cancer	7.05e-06	2.68e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PIK3CA—lung cancer	7.04e-06	2.67e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—lung cancer	7.01e-06	2.66e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTGS2—lung cancer	7.01e-06	2.66e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EGFR—lung cancer	7.01e-06	2.66e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CA—lung cancer	7e-06	2.66e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NRAS—lung cancer	7e-06	2.66e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	6.81e-06	2.59e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—lung cancer	6.81e-06	2.59e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—HRAS—lung cancer	6.81e-06	2.58e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—lung cancer	6.77e-06	2.57e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—HRAS—lung cancer	6.75e-06	2.56e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—KRAS—lung cancer	6.73e-06	2.55e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	6.7e-06	2.55e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK3—lung cancer	6.7e-06	2.54e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—lung cancer	6.69e-06	2.54e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—lung cancer	6.65e-06	2.53e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—KRAS—lung cancer	6.62e-06	2.51e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CA—lung cancer	6.62e-06	2.51e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—APOA1—lung cancer	6.61e-06	2.51e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—lung cancer	6.6e-06	2.5e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—lung cancer	6.6e-06	2.5e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—lung cancer	6.59e-06	2.5e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—lung cancer	6.52e-06	2.47e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL6—lung cancer	6.52e-06	2.47e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—HRAS—lung cancer	6.51e-06	2.47e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—lung cancer	6.48e-06	2.46e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—HRAS—lung cancer	6.48e-06	2.46e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL6—lung cancer	6.46e-06	2.45e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EGFR—lung cancer	6.37e-06	2.42e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—HRAS—lung cancer	6.3e-06	2.39e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL6—lung cancer	6.23e-06	2.37e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—HRAS—lung cancer	6.2e-06	2.35e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL6—lung cancer	6.2e-06	2.35e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CA—lung cancer	6.18e-06	2.35e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTEN—lung cancer	6.11e-06	2.32e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CA—lung cancer	6.08e-06	2.31e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CG—lung cancer	6.03e-06	2.29e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL6—lung cancer	6.03e-06	2.29e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KRAS—lung cancer	6.02e-06	2.29e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—lung cancer	6.01e-06	2.28e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—lung cancer	5.98e-06	2.27e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—lung cancer	5.96e-06	2.26e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL6—lung cancer	5.93e-06	2.25e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—lung cancer	5.88e-06	2.23e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—EP300—lung cancer	5.83e-06	2.21e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—lung cancer	5.75e-06	2.18e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—POMC—lung cancer	5.74e-06	2.18e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—lung cancer	5.72e-06	2.17e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—HRAS—lung cancer	5.72e-06	2.17e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—HRAS—lung cancer	5.63e-06	2.14e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CREBBP—lung cancer	5.59e-06	2.12e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—lung cancer	5.56e-06	2.11e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	5.53e-06	2.1e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—lung cancer	5.48e-06	2.08e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL6—lung cancer	5.47e-06	2.08e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—lung cancer	5.4e-06	2.05e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL6—lung cancer	5.38e-06	2.04e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—lung cancer	5.35e-06	2.03e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CD—lung cancer	5.3e-06	2.01e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ALB—lung cancer	5.24e-06	1.99e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—HRAS—lung cancer	5.12e-06	1.94e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—lung cancer	5.05e-06	1.92e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—lung cancer	4.97e-06	1.89e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL6—lung cancer	4.9e-06	1.86e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CB—lung cancer	4.62e-06	1.76e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS2—lung cancer	4.58e-06	1.74e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—lung cancer	4.52e-06	1.72e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CA—lung cancer	4.31e-06	1.64e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTEN—lung cancer	3.99e-06	1.52e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—EP300—lung cancer	3.81e-06	1.45e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—lung cancer	3.52e-06	1.34e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CA—lung cancer	2.82e-06	1.07e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—lung cancer	2.3e-06	8.74e-06	CbGpPWpGaD
